TEL-AVIV, Israel, January 2, 2018 /PRNewswire/ --
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) announced today that it has filed an international patent application with the PCT authorities on methods for testing which cannabinoids or combinations of cannabinoids are likely be effective in individual patients.
(Logo: http://mma.prnewswire.com/media/485543/Cannabics_Logo.jpg )
The determination is made by testing the effects of cannabinoids on CTCs (Circulating Tumor Cells) and biopsies of cancer patients. The integrated approach brings together cannabinoids research, Genetic markers, CTC counting and detection methods, and a drug sensitivity test for cannabinoids developed by Cannabics Pharmaceuticals. This unique method expands the company's proprietary technology of developing a more precise tool for personalization of cannabinoids based medicine as well as accelerating drug discovery.
About Cannabics Pharmaceuticals Inc.
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a U.S based public company, is dedicated to the development of Personalized Anti-Cancer and Palliative treatments. The Company's R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and clinical research. The Company's focus is on harnessing the therapeutic properties of natural Cannabinoid formulations and diagnostics. Cannabics engages in developing individually tailored natural therapies for cancer patients, utilizing advanced screening systems and personalized bioinformatics tools.
Disclaimer:
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-K Report filed on December 8th, 2017. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.
http://www.cannabics.com
Contact: Cannabics Pharmaceuticals, Inc., +1-877-424-2429, [email protected]
SOURCE Cannabics Pharmaceuticals Inc.
Advertisement
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) announced today that it has filed an international patent application with the PCT authorities on methods for testing which cannabinoids or combinations of cannabinoids are likely be effective in individual patients.
Advertisement
(Logo: http://mma.prnewswire.com/media/485543/Cannabics_Logo.jpg )
The determination is made by testing the effects of cannabinoids on CTCs (Circulating Tumor Cells) and biopsies of cancer patients. The integrated approach brings together cannabinoids research, Genetic markers, CTC counting and detection methods, and a drug sensitivity test for cannabinoids developed by Cannabics Pharmaceuticals. This unique method expands the company's proprietary technology of developing a more precise tool for personalization of cannabinoids based medicine as well as accelerating drug discovery.
About Cannabics Pharmaceuticals Inc.
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a U.S based public company, is dedicated to the development of Personalized Anti-Cancer and Palliative treatments. The Company's R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and clinical research. The Company's focus is on harnessing the therapeutic properties of natural Cannabinoid formulations and diagnostics. Cannabics engages in developing individually tailored natural therapies for cancer patients, utilizing advanced screening systems and personalized bioinformatics tools.
Disclaimer:
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-K Report filed on December 8th, 2017. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.
http://www.cannabics.com
Contact: Cannabics Pharmaceuticals, Inc., +1-877-424-2429, [email protected]
SOURCE Cannabics Pharmaceuticals Inc.
